05/04/2025
Weight loss continues after balloon deflates in contrast to GLP-1 injectables, where weight gain after stopping injections is common:
486 patients, were treated with the Allurion Balloon at a single, high-volume bariatric centre and assessed monthly with the Allurion App, Connected Scale, and Health Tracker as part of their Allurion Program.
Over one year, participants were given virtual access to a team of registered dieticians. A weekly check-up was conducted for the first month, followed by biweekly check-ups for the subsequent three months, and monthly check-ups for the remaining eight months.The average weight reduction of 10.5% at four months on the Allurion Programme, improving to 13.7% at one year probably because of the Programme’s ongoing virtual guidance and support.
Previous studies evaluating GLP-1 drugs indicate that after discontinuation of the drug and lifestyle intervention program, patients regained approximately two-thirds of the weight they had lost.1-3
Refs:
1. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.
2. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48.
3. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425.
